In this video, presented on Rheuma TV, explores Iguratimod (T-614)—a conventional synthetic disease-modifying antirheumatic drug (csDMARD) used in the management of Rheumatoid Arthritis (RA). The session covers its pharmacology, pharmacodynamics, and clinical mechanism of action, including its role in inhibiting NF-κB activation, suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, IL-17), downregulating immunoglobulin production, and regulating bone metabolism by suppressing osteoclast activity while promoting osteoblast differentiation.
